S-1: Mangoceuticals Registers Shares for Resale, Outlines Growth Strategy

Mangoceuticals registers shares for resale by selling stockholders, detailing its growth strategy focused on marketing, telemedicine, and subscription plans.

Summary

• Mangoceuticals has registered 16,166,667 shares of common stock for resale by its selling stockholders.
• The shares consist of those issuable upon exercise of warrants and conversion of Series B Preferred Stock.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• Proceeds from any exercise of warrants will be used for general working capital.
• Mangoceuticals' growth strategy includes utilizing various marketing channels, investing in its telemedicine platform, and providing subscription plans.
• The company markets Mango ED and Mango GROW products, which are compounded medications for erectile dysfunction and hair growth, respectively.
• These products are sold online through the company's website, www.MangoRX.com.
• The company relies on a related party, Epiq Scripts, for pharmacy and compounding services.
• The company is subject to FDA regulations regarding compounded drugs and promotional activities.
• The company has entered into a Patent Purchase Agreement to acquire patents related to prevention of infections, including the common cold, respiratory diseases, and orally transmitted diseases such as human papillomavirus (HPV).

Sentiment

Score: 5

Explanation: The document presents a mix of positive and negative aspects. While it highlights growth strategies and market opportunities, it also acknowledges significant risks, reliance on related parties, and the need for additional funding. The sentiment is neutral overall.

Positives

• The company is expanding its marketing efforts to attract more customers.
• The company is investing in its telemedicine platform to enable sales throughout the United States.
• The company is providing subscription plans for recurring revenue.
• The company has acquired patents related to prevention of infections.

Negatives

• The company will not receive any proceeds from the sale of shares by the selling stockholders.
• The company relies on a related party, Epiq Scripts, for pharmacy and compounding services.
• The company is subject to FDA regulations regarding compounded drugs and promotional activities.
• The company's Mango ED and Mango GROW products have not been, and will not be, approved by the FDA.

Risks

• The company needs additional funding, and the availability and terms of such funding are uncertain.
• The company has a limited operating history and has generated only limited revenues to date.
• The company faces intense competition from companies with greater resources and experience.
• The company's Mango ED and Mango GROW products have not been, and will not be, approved by the FDA.
• The company is significantly reliant on related party transactions.
• The company's business is exposed to risks associated with credit card and other online payment chargebacks and fraud.
• The company's business could be disrupted by catastrophic events and man-made problems.
• The company may not be able to maintain its listing on Nasdaq.

Future Outlook

The company plans to continue using the same marketing and management strategies and continue providing a quality product with excellent customer service while also seeking to expand its operations organically or through acquisitions as funding and opportunities arise.

Industry Context

The company operates in the growing mens wellness telemedicine sector, competing with larger pharmaceutical companies and online direct-to-consumer companies.

Comparison to Industry Standards

• The document references market reports from Verified Market Research and Grand View Research regarding the erectile dysfunction drugs market.
• It mentions competitors like Hims & Hers Health, Inc., Roman, Pfizer (Viagra), Lilly ICOS LLC (Cialis), Merck & Co. (Propecia), and Johnson & Johnson (Rogaine).
• The document cites a study by LetsGetChecked regarding the prevalence of erectile dysfunction in the U.S.
• It also references a market study by The Insight Partners regarding the hair loss prevention products market.

Related Party Transactions

• The company has entered into a Master Services Agreement and Statement of Work with Epiq Scripts, LLC, a related party, 51% owned and controlled by Jacob D. Cohen, our Chairman and Chief Executive Officer.
• The company has entered into a Consulting Agreement with Epiq Scripts.
• The company has entered into a First Addendum to Master Services Agreement with Epiq Scripts.
• The company has entered into a Consulting Agreement with PHX Global, LLC, which is owned by Peter Casey Jensen, who was a member of the Board of Directors of American International.
• The company has entered into a Consulting Agreement with Ezekiel Elliott.
• The company has entered into a Consulting Agreement with David Sandler.
• The company has entered into a Consulting Agreement with Hsiaoching Chou.
• The company has entered into a service agreement with Greentree Financial Group, Inc., where Eugene M. Johnston, our Chief Financial Officer, serves as Audit Manager.
• The company has entered into a Consulting Agreement with DojoLabs Group, Inc.
• The company has entered into Advisor Agreements with Dr. Brian Rudman and Mr. Jarrett Boon.
• The company has entered into Consulting Agreements with Sultan Haroon, John Helfrich, Justin Baker, and Maja Matthews, each of whom is also an employee of Epiq Scripts.

Stakeholder Impact

• Shareholders may experience dilution from future sales of common stock or preferred stock.
• The company's ability to attract and retain customers will depend on its ability to successfully implement and improve its customer experience.
• The company's ability to compete will depend on its ability to maintain and grow the value of the Mango brand.
• The company's ability to generate commercial revenues will depend on the degree of market acceptance of its products.

Next Steps

• The selling stockholders may offer and sell shares of common stock from time to time.
• The company will continue to implement its growth strategy.
• The company will continue to monitor the closing bid price of the Common Stock and will, if necessary, implement a reverse stock split of its outstanding securities, to regain compliance with the Minimum Bid Price Requirement.

Key Dates

Keywords

Mangoceuticals, common stock, resale, warrants, Series B Preferred Stock, telemedicine, Epiq Scripts, compounding, FDA, marketing, Mango ED, Mango GROW